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  A plethora of statin survival trials and meta-analyses 
have demonstrated a substantial reduction in cardiovascular 
disease (CVD) morbidity and mortality, mainly related   
to a low-density lipoprotein cholesterol (LDL-C) reduction 
[1]. One of them, the prospective, randomised, double-blind, 
secondary prevention Treating to New Targets (TNT, n = 
10,001) trial, randomised patients to either 10 or 80 mg/day 
of atorvastatin. During a 5-year period the 10 mg/day 
patients had a rate of major CVD events of 10.9%, while 
those randomised to 80 mg/day had an 8.7% event rate. This 
was despite the concurrent and successful treatment of other 
CVD risk factors, the 22% (p<0.001) CVD risk reduction 
compared with atorvastatin 10 mg/day, and the achievement 
of LDL-C levels of 77 mg/dl (well below those suggested by 
guidelines at that time) [2]. Similar were the data from the 
prespecified  post hoc subgroup analysis of TNT that 
included patients (n = 1,401) with type 2 diabetes mellitus 
(T2DM) that had mild to moderate chronic kidney disease 
(CKD, a microvascular complication of DM) or normal renal 
function [3]. Compared with 10 mg of atorvastatin, 80 mg of 
atorvastatin reduced the relative risk (RR) of major CVD 
events by 35% (absolute event rate 21 vs 14%; hazard ratio 
(HR) = 0.65; 95% confidence interval (CI) = 0.43-0.98;   
p = 0.04) in those with CKD and by 10% in patients   
with T2DM and normal renal function (14.8 vs 14%;   
HR = 0.90; p = 0.56) [3]. In any case (with or without 
diabetic nephropathy) a residual CVD risk was present, as in 
all statin survival trials [1]. In the Steno-2 study, intensive 
multifactorial intervention in patients with T2DM during a  
5-year follow-up, significantly reduced CVD events   
(HR = 0.47, 95% CI = 0.24-0.73, p = 0.008) and CVD 
mortality (HR = 0.43, 95% CI = 0.19-0.94, p = 0.04), but  
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failed to prevent the development or the progression of 
microvascular complications of T2DM in up to 50% of 
patients [4, 5]. This contributed to a lesser reduction of CVD 
mortality or morbidity rates, and was recorded despite the 
effort to control glycaemia, blood pressure, body weight, 
smoking, physical activity, and LDL-C levels [4,5]. Thus, 
residual risk is related both to macrovascular complications 
connected to atherogenic dyslipidaemia [high triglycerides 
(TGs) and low high density lipoprotein cholesterol (HDL-C) 
levels, prevalent in DM] and to microvascular complications 
of T2DM, which contribute to the excess CVD and all cause 
morbidity and mortality [6-8].  
  The gains in CVD prevention and treatment are being 
challenged by the impact of global epidemics of obesity, 
metabolic syndrome (MetS) and T2DM [9]. Recent data 
suggest a possible reversal in CVD mortality rates, 
especially in younger men and women [10, 11]. These trends 
have a negative impact on life expectancy (each year 4.3 
million CVD deaths are reported in Europe [12]) and quality 
of life as well as on the cost of managing CVD, estimated in 
2008 at about $450 billion per annum in the United States 
(US) [13] and $300 billion in Europe [12]. DM-related 
complications, including CVD, CKD, neuropathy, blindness, 
and lower-extremity amputation, are significant causes of 
increased morbidity and mortality, and further increase the 
economic burden on health care systems. In 2050, the 
number of people in the US with diagnosed DM is estimated 
to grow to 48.3 million, from 20 million in 2005 [14].  
  It was thought until recently that current standards of 
care, such as effective glycaemic control, reduce CVD 
events (on a very long term basis), and improve micro- 
vascular complications of DM [diabetic retinopathy (DR), 
nephropathy (DNeph) or neuropathy (DNeur) [6]. A recent 
meta-analysis of 14 clinical trials that randomised 28,614 
participants with T2DM (15,269 to intensive and 13,345 to 
conventional glycaemic control) showed that intensive 
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cause or macrovascular and microvascular disease (as a 
composite outcome or retinopathy or nephropathy or 
amputations alone) [15], while compared with conventional 
glycaemic control it increased the risk of severe 
hypoglycaemia by 30%. The latter might lead to increased 
mortality rates [15]. If intensive glycaemic control is 
dangerous and does not prevent microvascular complications 
of DM, as we believed until recently, then what can?   
Is it possible that arterial hypertension or atherogenic 
dyslipidaemia (both closely related to DM) may contribute  
to the pathogenesis of microvascular complications of   
DM [16]? The Action to Control Cardiovascular Risk in 
Diabetes - Eye (ACCORD-EYE) study showed that there 
was no significant effect of intensive vs standard blood-
pressure control on the progression of macrovascular and at 
least the 1 microvascular complication (DR) of DM during a 
4 year follow-up [17]. On the other hand it seems that there 
is a link between atherogenic dyslipidaemia and micro- 
vascular complications of DM [18, 19]; this is further 
confirmed by data suggesting that combinations or mono- 
therapies of hypolipidaemic drugs (through hypolipidaemic 
[20] or off-target effects) improve existing or prevent new 
microvascular complications of DM [21, 22] thus providing 
a fresh approach for the treatment of this feature of DM   
that still has unmet needs [21, 22]. There are some data 
suggesting that this might be one way to solve this problem 
[7,16,23]. 
A. DIABETIC RETINOPATHY 
  The number of Americans 40 years or older with DR and 
vision-threatening DR (VTDR), the leading cause of 
blindness in the Western world, will triple in 2050, from 5.5 
million in 2005 to 16.0 million for DR and from 1.2 million 
in 2005 to 3.4 million for VTDR [24]. Increases among those 
65 years or older will be more pronounced (2.5 million to 9.9 
million for DR and 0.5 million to 1.9 million for VTDR) 
[24]. Thus, DR and VTDR will grow to be even more 
significant public health problems. In the Diabetes Control 
and Complications Trial/Epidemiology of Diabetes Inter- 
ventions and Complications (DCCT/EDIC) study, among 
others, the severity of DR and macular oedema were 
positively associated with high TGs and negatively 
associated with HDL-C levels [25]. This is the reason that 
the beneficial effect of fenofibrate on DR did not come as a 
total surprise. Data from the Fenofibrate Intervention and 
Event Lowering in Diabetes (FIELD) study (n = 9,795 
patients, aged 50-75 years with T2DM) [26] showed   
that fenofibrate had significant preventive effect on the 
development of DR, reducing first laser treatment (a 
predefined tertiary endpoint of FIELD) by 31% (p = 0.0002) 
and proliferative retinopathy by 30%, (p = 0.015) [27]. The 
benefit of treatment was enhanced in patients without prior 
retinopathy [relative risk reduction (RRR) for all laser events 
by 49%, p = 0.002 in DR free patients, compared with 24%, 
p = 0.01, in patients with a history of DR]. These effects 
were achieved within 8 months of treatment, and increased 
during the study [27]. 
  The ACCORD study [28] randomized 5,518 high risk 
T2DM patients at target for LDL-C (100 mg/dl) on 
simvastatin to fenofibrate or placebo. Fenofibrate treatment 
lowered TGs by 22% from baseline vs 8.7% with simvastatin 
alone, and raised HDL-C by 8.4 vs 6.0% with simvastatin 
alone (p<0.05). The study failed to demonstrate a benefit for 
a composite of CVD death, nonfatal myocardial infarction 
(MI) or nonfatal stroke [28]. A subgroup of patients with 
atherogenic dyslipidaemia had a 31% (p < 0.05) reduction in 
primary endpoint (death and major CVD events) with 
combination treatment compared with simvastatin treatment 
alone [29]. Similar results were reported from all fibrate 
trials [29].  
  The ACCORD-EYE study [17] showed that intensive 
glycaemia therapy significantly reduced the risk of 
progression of DR. However, tight glycaemic control [< 7% 
glycosylated haemoglobin (HbA1c)] was also associated with 
an increased rate of death from any cause after a mean of 3.5 
years of follow-up compared with the standard strategy [17]. 
The ACCORD EYE study also reported a beneficial effect of 
fenofibrate on the progression of DR (6.5 vs 10.2% with 
placebo; p = 0.006; both groups were on simvastatin) [17], 
while there was no significant effect of intensive vs standard 
blood-pressure control on the progression of DR at 4 years 
(10.4 vs 8.8%, p = 0.29) [17]. 
  In the Collaborative Atorvastatin Diabetes Study 
(CARDS), a primary prevention study in T2DM patients, 
there was no evidence of a significant benefit on the 
progression of DR among patients treated with atorvastatin 
[30]. It should also be noted that in the Steno-2 study [4,5] 
DR developed or progressed in 48% of patients treated with 
intensive multifactorial therapy (including optimal statin 
treatment) over a 7.8-year period [4,5].  
  This evidence supports a beneficial role for fenofibrate 
treatment in preventing the development or progression of 
DR in T2DM, especially among patients at the early stages 
of DR [7]. The use of fenofibrate in T2DM patients with 
atherogenic dyslipidaemia appears useful, because besides 
its effect on macrovascular (residual) CVD risk [28,29], it 
may also reduce microvascular complications of DM [29].  
B. DIABETIC NEPHROPATHY 
  DNeph expressed as a loss of kidney function (reduced 
glomerular filtration rate-GFR) or as albuminuria/proteinuria 
is a major CVD risk factor. CKD (with a GFR < 60 ml/min/ 
1.73 m
2) was characterised in guidelines as a coronary heart 
disease (CHD) equivalent [31]. The GREACE (Greek 
Atorvastatin and Coronary Heart Disease Evaluation) study 
showed an improvement in kidney function (mean GFR 
increase by 12%) over a period of 3 years in 800 patients 
treated with atorvastatin, compared with a decrease in kidney 
function by 4% in placebo patients [32]. The TNT (n = 
10,001) study showed that statin-related improvement in 
estimated GFR (eGFR) was significantly greater in patients 
with CKD treated with atorvastatin 80 mg (9.9%, p<0.0001) 
compared with those with CKD on 10 mg daily (6.6%) [33, 
34], while those with normal renal function had lower 
increases in GFR at both the 10 and the 80 mg/day 
atorvastatin doses [33]. This was related with a greater RRR 
(32%, p = 0.0003) in primary endpoint (death and all major 
CVD events) in patients with stage 3 CKD (n = 3,107, GFR 
30-59 ml/min/1.73m
2) than in patients with normal renal 
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  In a meta-analysis (1,384 patients during 24 weeks of 
follow-up) investigating the effect of statins on albuminuria/ 
proteinuria regardless of aetiology statins reduced 
albuminuria (11 studies) and proteinuria (4 studies) in 13 of 
15 studies [35]; the reduction in excretion being greater 
among studies with higher baseline albuminuria/proteinuria. 
The change in excretion was 2% (95% CI = -32 to 35%)  
for those with excretion < 30 mg/day, -48% (95% CI = -71 
to -25%) for those with excretion of 30-300 mg/day and -
47% (95% CI = -67 to -26%) for those with excretion > 300 
mg/day [35]. Statins may have a beneficial effect on 
albuminuria/proteinuria, however, the validity of this 
finding, and whether this effect translates into reduction   
of CVD or end-stage renal disease (ESRD) requires larger 
studies [35].  
  In patients with T2DM the effect of statins on urinary 
albumin excretion (UAE) may be different. In CARDS [36], 
a randomized, placebo-controlled trial that included 2,838 
patients with T2DM and free of CVD at baseline, 34% (n = 
970) of the patients had an eGFR of 30-59 ml/min/1.73m
2. In 
these patients atorvastatin 10 mg/day was associated with a 
modest improvement in the annual change in eGFR (p = 
0.01), and with substantial reduction in major CVD events 
(42%) and stroke (61%) [36]. At baseline, 21.5% of patients 
had albuminuria and an additional 6.8% developed 
albuminuria during follow-up. Atorvastatin did not influence 
the incidence of albuminuria or regression to normo- 
albuminuria [36]. In the Use of Rosuvastatin versus 
Atorvastatin iN type 2 diabetes mellitUS patients (URANUS) 
trial [37] the effect of rosuvastatin or atorvastatin on UAE 
was determined in T2DM. This was a randomized, double-
blind, parallel-group, response-based design study that 
compared rosuvastatin 10 mg (titrated to 40 mg) with 
atorvastatin 10 mg (titrated to 80 mg) in T2DM patients with 
dyslipidaemia. Results suggest that no significant change 
from baseline in UAE was observed for either treatment 
group or between-treatment groups at 16 weeks, and UAE 
for both treatment groups remained within normal limits 
[37]. 
  In a recent post hoc analysis of FIELD [38], fenofibrate 
reduced albuminuria and slowed eGFR loss over 5 years, 
despite initially and reversibly increasing plasma creatinine. 
In the fenofibrate group there was a 5.0 ml/min/1.73 m
2 
(95% CI = 2.3-7.7, p < 0.001) smaller loss of renal function 
compared with placebo [38]. Fenofibrate reduced urine 
albumin concentrations and hence albumin/creatinine   
ratio by 24% (p < 0.001), with 14% less progression and 18% 
more albuminuria regression (p < 0.001) than placebo. Thus, 
fenofibrate reduced UAE and delayed GFR impairment in 
T2DM [38], 2 independent predictors of CVD events and 
total mortality in T2DM patients [39].  
C. DIABETIC PERIPHERAL NEUROPATHY AND 
LOWER-EXTREMITY AMPUTATION 
  The age-adjusted rate of lower-extremity amputation 
(LEA) in DM patients is approximately 15 times that of the 
non-diabetic population. Over 50,000 LEAs were performed 
on individuals with DM in the United States in 1985 [40]. 
Among individuals with DM, diabetic peripheral neuropathy 
(DPN), peripheral arterial disease (PAD), and impaired 
microvascular circulation are the major predisposing factors 
for LEA. Lack of adequate foot care and infection are 
additional risk factors [40]. A study from US demonstrated 
that the prevalence of patients with DPN symptoms was 
high, and that DPN was alarmingly underdiagnosed in study 
participants [41]. These could influence the development of 
severe foot complications like diabetic foot ulcer, and even 
possibly increase the risk of lower extremity amputation. 
This study is a stimulus to help educators develop targeted 
education and intervention programs for DPN and diabetic 
foot [41]. 
  The FIELD study showed that fenofibrate reduced the 
number of lower-extremity non-traumatic amputations (a 
prespecified tertiary outcome) compared with placebo (38%, 
p = 0.011) [42]. The cumulative hazard curves showed a 
reduction in amputation rates that seemed to diverge from 
the placebo rates after just 1.5 years of fenofibrate use. The 
reduction in the risk of first amputation (36%, p = 0.02)   
and minor amputation (there was no known large-vessel 
disease, 47%, p = 0.027) were striking, by contrast with a 
non-significant reduction (7%, p = 0.79) for major (large-
vessel-related) amputations [42]. Of note, atorvastatin 
reduces amputation in T2DM mice with PAD through   
p53 degradation [43]. Although it has been hypothesised   
that statins have a favourable effect on DPN, independent  
of its lipid-lowering effect by demonstrating restoration or 
preservation of microcirculation of the sciatic nerve [44], 
there are no actual data on humans.  
D. DIABETIC AUTONOMIC NEUROPATHY  
  (DAN): is a major microvascular complication because it 
is associated with high morbidity and mortality (sudden 
cardiac death and malignant ventricular arrhythmias) [45-
47]. The evolution of DAN is related to a gradual increase of 
sympathetic tone that overrides the reduced parasympathetic 
tone until the patients reach a full (autonomic nervous 
system) cardiac denervation, resulting in a permanent and 
significant decrease in heart rate variability (HRV) in an 
increase in resting heart rate [45]. The aetiology of DAN has 
not been fully elucidated, but increased oxidative stress may 
be involved [48,49]. Hyperglycaemia causes oxidative stress 
through the increased activity of the polyol route, and is 
associated with increased production of advanced glycation 
end-products (AGEs), another possible cause of DAN [49]. 
We have shown that atorvastatin improves DAN, increasing 
parasympathetic tone and decreasing sympathetic tone, in 
dyslipidaemic patients with or without CVD, but free of DM 
at baseline [50]. Fluvastatin seems to have a beneficial effect 
on DAN and reduces sympathetic tone in patients with DM 
[51], while the beneficial effect of atorvastatin on diabetic 
foot was attributed partly to favourable action on the   
DAN and DPN [52]. Other lipid-lowering drugs (fibrates or 
omega-3 fat) have not been tested in that field. 
  Any potential explanations for the observed discrepancies 
in results of various studies mentioned above could be 
explained by differences in study populations, study protocols, 
study duration and drug specific properties. Another issue 
was that all studies used assessed eGFR using the MDRD 
equation. However, eGFR has limitations in comparison 
with the measurement of GFR with Cr-EDTA, [53], but Cr-
EDTA can not be used in routine practice. Hypolipidaemic Treatment for Microvascular Complications of Diabetes  The Open Cardiovascular Medicine Journal, 2012, Volume 6    31 
  The beneficial effects of drug treatment for dyslipidaemia 
on microvascular complications of DM are probably related 
both to the hypolipidaemic and the "pleiotropic" effects of 
these drugs [54]. A plethora of additional effects has been 
ascribed as "pleiotropic" effects, and these may be essential 
for manifestation of the clinical benefit by these drugs. This 
interpretation is supported by the fact that improvement of 
renal function became evident from week 6 of the treatment 
[32].  
  Therefore, it seems that some lipid-lowering drugs have a 
favourable effect on microvascular complications of DM 
when administered in combination or as monotherapy. Much 
remains to be clarified in this field. It is of outmost interest 
to find out whether or not microvascular complications share 
a common pathogenesis and whether or not a hypolipidaemic 
drug can be effective against microvascular complications. 
This has not been investigated yet, probably because micro- 
vascular complications of DM are related to several 
specialties (e.g. internal medicine, diabetology, nephrology, 
ophthalmology, neurology, cardiology and vascular surgery), 
making it difficult to coordinate the efforts to elucidate their 
pathogenesis and treatment. It is therefore useful to explore 
the effects of lipid-lowering in the pathogenesis, prevention 
or treatment of microvascular complications of DM, because 
these are significant public health problems and there is still 
no standard therapy for them. 
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